Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Myeloma more likely to go untreated in dual Medicare-Medicaid recipients

Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.

Key clinical point: Older patients, African Americans, and low-income patients may be less likely to receive multiple myeloma treatment.

Major finding: Factors significantly associated with no systemic treatment included older age (adjusted odds ratio, 1.07 per year), African American descent (aOR, 1.26), and dual Medicare-Medicaid enrollment (aOR, 1.21).

Study details: A retrospective cohort analysis including data on 3,814 patients with active multiple myeloma in the Surveillance, Epidemiology, and End Results–Medicare database from 2007 to 2011.

Disclosures: The research was supported by the National Cancer Institute. The investigators reported having no financial disclosures.

Source: Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.

Read the article.

Citation:

Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.